Location of Repository

Glycated albumin suppresses glucose-induced insulin secretion by impairing glucose metabolism in rat pancreatic β-cells

By Takayuki Shiraki, Yoshikazu Miura, Tokihiko Sawada, Toshie Okada, Yuhki Sakuraoka, Takashi Muto and Keiichi Kubota
Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3079599
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Preview

    Citations

    1. (2008). AM: Mechanism of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nature Clin Pract Endocrinol Metab
    2. (1992). Aschcroft SJH: The sulfonylurea receptor. Biochim Biophys Acta
    3. (2001). Biochemistry and molecular cell biology of diabetic complications.
    4. (2007). Deferoxamine enhances anti-proliferative effect of interferon-γ against hepatocellular carcinoma cells. Cancer Lett
    5. (2000). DM: The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta
    6. (2001). DM: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses.
    7. (2003). Glucagon-like peptide-1 induces a cAMP-dependent increase of [Na +]i associated with insulin secretion in pancreatic β-cells.
    8. (1992). Habener JF: Insulinotropic action of glucagon-like peptide-1-(7-37) in diabetic and nondiabetic subjects. Diabetes Care
    9. (1993). Henquin JC: Activation of muscarinic receptors increases the concentration of free Na+ in mouse pancreatic β cells. FEBS Lett
    10. (1995). Henquin JC: Muscarinic stimulation exerts both stimulatory and inhibitory effects on the concentration of cytoplasmic Ca 2+ in the electrically excitable pancreatic β-cell.
    11. (1984). HP: The ionic, electrical, and secretory effects of endogenous cyclic adenosine monophosphate in mouse pancreatic B cells: studies with forskolin. Endocrinology
    12. Identification of arginine as a precursor of endothelium-derived relaxing factor.
    13. (2003). Imaizumi T: Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy.
    14. (2009). Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer’s Disease. J Alzheimer Dis
    15. (1999). Kaowaki T: Role of NADH shuttle system in glucoseinduced activation of mitochondrial metabolism and insulin secretion. Science
    16. (1963). Lazarow A: Immunoassay of insulin. Two-antibody system, plasma insulin level of normal, subdiabetic, and diabetic rats. Diabetes
    17. (1996). Malaisse WJ: Insulinotropic action of methyl pyruvate: enzyme and metabolic aspects. Arch Biochem Biophys
    18. (1984). Malaisse-Lagae F: The role of cyclic AMP in insulin release. Experientia
    19. (2003). Matschinsky FM: Distinguishing features of leucine and α-ketoisocaproate sensing in pancreatic β-cells. Endocrinology
    20. (1986). Matschinsky FM: Pancreatic islet glucose metabolism and regulation of insulin secretion. Diabetes Metab Rev
    21. (2008). Miele C: In skeletal muscle advanced glycation endproducts (AGEs) inhibit insulin action and induce the formation of multimolecular complexes including the receptor for AGEs.
    22. (2000). Miwa I: Difference in mechanism between glyceraldehyde- and glucose-induced insulin secretion from isolated rat pancreatic islets.
    23. (1998). MP: Glycated albumin stimulates gene expression in glomerular mesangial cells: involvement of the transforming growth factor-β system. Kidney Int
    24. Murtiashaw MH: From Nonenzymatic glucosylation of lysine residues in albumin.
    25. (2003). Obberghen E: Human glycated albumin affects glucose metabolism in L6 skeletal muscle cells by impairing insulin-induced insulin receptor substrate (IRS) signaling through a protein kinase Cα-mediated mechanism.
    26. (2002). Palace MR: Diabetes and advanced glycation end products.
    27. (2005). Panten U: Mechanism of the insulin-releasing action of α-ketoisocaproate and related α-keto acid anions. Mol Pharmacol
    28. (1978). PM: The glycosylation of hemoglobin: relevance to diabetes mellitus. Science
    29. (1993). The DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin dependent diabetes mellitus.
    30. (1996). The use of aminoguanidine, a selective iNOS inhibitor, to evaluate the role of nitric oxide in the development of autoimmune diabetes. Methods
    31. (1979). Todo S: Simple method for the collection of pancreatic islets by the use of Ficoll-Conray gradient. Endocrinol Jpn
    32. (1985). Tsien RY: A new generation of Ca 2+ indicators with greatly improved fluorescence properties.
    33. (2002). Vascular smooth muscle cell activation by glycated albumin (Amadori adducts). Hypertension
    34. (2008). Yada T: Sub-chronic stimulation of glucocorticoid receptor impairs and mineralocorticoid receptor protects cytosolic Ca 2+ responses to glucose in pancreatic β-cells.
    35. (2009). ZA: Advanced glycation end products inhibit glucose-stimulated insulin secretion through nitric oxide-dependent inhibition of cytochrome c oxidase and adenosine triphosphate synthesis. Endocrinology
    36. (1994). Ziyadeh FN: Amadori glucose adducts modulate mesangial cell growth and collagen gene expression. Kidney Int

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.